{"id":"placebo-to-rizatriptan-tablets","safety":{"commonSideEffects":[{"rate":"9","effect":"Dizziness"},{"rate":"8","effect":"Somnolence"},{"rate":"5","effect":"Asthenia/fatigue"},{"rate":"2","effect":"Chest pain/pressure"},{"rate":"1","effect":"Palpitations"},{"rate":"4","effect":"Nausea"}]},"_chembl":null,"_fixedAt":"2026-03-30T12:49:25.987542","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rizatriptan binds to 5-HT1B and 5-HT1D receptors on intracranial blood vessels and trigeminal nerve terminals. This causes vasoconstriction of dilated cranial arteries and reduces the release of vasoactive neuropeptides involved in migraine pathophysiology, thereby terminating acute migraine attacks.","oneSentence":"Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:02.329Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute treatment of migraine with or without aura in adults"}]},"_fixedFields":["pubmed(2)"],"trialDetails":[{"nctId":"NCT04163185","phase":"PHASE3","title":"Initiating Early Control of Migraine Pain and Associated Symptoms","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-10-08","conditions":"Migraine","enrollment":302},{"nctId":"NCT04384367","phase":"PHASE3","title":"Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2022-12-30","conditions":"Migraine","enrollment":2068},{"nctId":"NCT00111722","phase":"PHASE3","title":"Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05-27","conditions":"Migraine","enrollment":393},{"nctId":"NCT00095004","phase":"PHASE3","title":"Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-10-21","conditions":"Migraine","enrollment":167},{"nctId":"NCT00111709","phase":"PHASE3","title":"Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05-27","conditions":"Migraine","enrollment":393},{"nctId":"NCT00092963","phase":"PHASE3","title":"Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-08-17","conditions":"Migraine","enrollment":529},{"nctId":"NCT00812006","phase":"PHASE3","title":"A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-03-24","conditions":"Migraine","enrollment":108},{"nctId":"NCT00894556","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-06-10","conditions":"Acute Migraine","enrollment":109},{"nctId":"NCT01001234","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-11-30","conditions":"Migraine, Acute","enrollment":1382},{"nctId":"NCT00516737","phase":"PHASE3","title":"Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-10-03","conditions":"Migraine","enrollment":207},{"nctId":"NCT00604812","phase":"PHASE1","title":"Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-12-17","conditions":"Migraine Disorders","enrollment":31},{"nctId":"NCT00899379","phase":"PHASE3","title":"Treatment of Multiple Attacks of Acute Migraine (0462-025)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-04","conditions":"Migraine Headache","enrollment":473},{"nctId":"NCT00250458","phase":"PHASE3","title":"Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-03","conditions":"Migraine","enrollment":346},{"nctId":"NCT00897949","phase":"PHASE3","title":"MK0462 in Treatment of Migraine With Recurrence (MK0462-022)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-03","conditions":"Migraine Headache","enrollment":1473},{"nctId":"NCT00897104","phase":"PHASE3","title":"MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-08","conditions":"Migraine Headache","enrollment":933},{"nctId":"NCT00443209","phase":"PHASE3","title":"Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-21","conditions":"Migraine","enrollment":1068},{"nctId":"NCT01306266","phase":"NA","title":"Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2011-02","conditions":"Chronic Post-traumatic Headache","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"recentPublications":[{"date":"1999 Apr","pmid":"15613223","title":"Pharmacokinetics of rizatriptan tablets during and between migraine attacks.","journal":"Headache"},{"date":"2001 Jun","pmid":"11440288","title":"Migraine treatment outcomes with rizatriptan in triptan-naive patients: a naturalistic study.","journal":"Clinical therapeutics"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to rizatriptan tablets","genericName":"Placebo to rizatriptan tablets","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches. Used for Acute treatment of migraine with or without aura in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}